Stool-based tests for colorectal cancer (CRC) screening show no significant difference in detecting advanced neoplasia overall, but for advanced serrated lesions specifically, the multitarget stool ...

Stool-based DNA testing can help bridge CRC screening gaps between rural and urban populations by providing timely follow-up. The study found no significant difference in follow-up times for ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

Please provide your email address to receive an email when new articles are posted on . Among all the CRC screening methods, CRC incidence and mortality rates were highest among those who received ...

Patients with an average risk for colorectal cancer (CRC) are candidates for noninvasive tests, such as multitarget stool DNA (mtsDNA), whereas those with a higher risk, including those with a family ...

Quality metrics for screening tests must evolve to mandate diagnostic resolution, ensuring financial and clinical incentives prioritize the complete screening continuum over initial test uptake.

"But for now, if you're willing and able to do a colonoscopy or stool-based test, don't switch to a blood test." Ladabaum also pointed out that, at a population level, the blood tests will be ...

Please provide your email address to receive an email when new articles are posted on . Annual fecal immunochemical testing was the most effective and cheapest CRC screening method for underserved ...

Time for a rear-ality check. Colorectal cancer rates have been rising among adults younger than 50 since the 1990s, a troubling trend that has perplexed scientists. Because of the increase in cases, ...

The American Cancer Society is adding some new testing options to its screening guideline for colorectal cancers – and for the first time, that includes a blood test. Colonoscopies are still ...

Bernstein lifted its Guardant Health price target to $200 after UnitedHealth's Shield coverage decision. Here's what it means ...